Hospital de Jerez Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2007
NCT00543127
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

roflumilast (daliresp) (1 trial)

Drugs in Phase 3 Trials (2)

anastrozole (arimidex) (1 trial)

fulvestrant (faslodex) (1 trial)

Drugs in Phase 2 Trials (4)

bendamustine (treanda) (1 trial)

mitoxantrone (novantrone) (1 trial)

rituximab (rituxan) (1 trial)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Lung Diseases, Obstructive (Phase 4)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 7